References:
1-Gowthami M. Arepally; Heparin-induced thrombocytopenia. Blood  2017; 129 (21): 2864–2872.
2- Franchini, Massimo, and Dino Veneri. ”Heparin-induced thrombocytopenia.” Recenti Progressi in Medicina  96.9 (2005): 433-435.
3- Arepally, Gowthami M., and Douglas B. Cines. ”Pathogenesis of heparin-induced thrombocytopenia.” Translational Research  225 (2020): 131-140.
4- Zoller, Marc, et al. ”Near fatal stent thrombosis in an aneurysmatic RCX as first manifestation of heparin induced thrombocytopenia (HIT) without thrombocytopenia.” BMC Cardiovascular Disorders  21.1 (2021): 1-5.
5-Warkentin, Theodore E. ”An overview of the heparin-induced thrombocytopenia syndrome.” Seminars in thrombosis and hemostasis . Vol. 30. No. 03. Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA., 2004.
6- Rice, Lawrence. ”Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient).” Archives of internal medicine  164.18 (2004): 1961-1964.
7- Warkentin, Theodore E., et al. ”Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.” (1994): 3691-3699.
8- Cuker, Adam, et al. ”American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.” Blood advances  2.22 (2018): 3360-3392.
9- Cuker, Adam, et al. ”Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis.” Blood, The Journal of the American Society of Hematology  120.20 (2012): 4160-4167.
10- Linkins, Lori-Ann, et al. ”Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines.” Chest  141.2 (2012): e495S-e530S.
11-Hogan, Marie, and Jeffrey S. Berger. ”Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management.” Vascular Medicine  25.2 (2020): 160-173.
12-McGowan, Kelly E., et al. ”Reducing the hospital burden of heparin-induced thrombocytopenia: impact of an avoid-heparin program.” Blood, The Journal of the American Society of Hematology  127.16 (2016): 1954-1959.
13- Warkentin, Theodore E. ”Heparin-induced thrombocytopenia: a clinicopathologic syndrome.” Thrombosis and haemostasis  82.08 (1999): 439-447.
14- Lo, G. K., et al. ”Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings.” Journal of Thrombosis and Haemostasis  4.4 (2006): 759-765.
15- Vatanparast, Rodina, et al. ”Evaluation of a pretest scoring system (4Ts) for the diagnosis of heparin-induced thrombocytopenia in a university hospital setting.” Postgraduate medicine  124.6 (2012): 36-42.
16- Arani, Naszrin, et al. ”A Case for Calculating 4T Scores: Predictive Value in the Diagnosis of Heparin-Induced Thrombocytopenia.” Blood  140.Supplement 1 (2022): 11344-11345.
17- Busche, Marc Nicolai, et al. ”Heparin-induced thrombocytopenia in a nonthrombocytopenic patient with toxic epidermal necrolysis causing fatal outcome: is HIT still a HIT?.” Journal of burn care & research  30.4 (2009): 747-751.
18- PHELAN, BRIAN K. ”Heparin-associated thrombosis without thrombocytopenia.” Annals of internal medicine  99.5 (1983): 637-638.
19- Greinacher, Andreas, et al. ”Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis.” Thrombosis and haemostasis  94.07 (2005): 132-135.